Brain cannabinoid receptor 2: Expression, function and modulation

Acta Pharmacologica Sinica

Volumn 38, Issue 3, 2017, Pages 312-316

  Chen, De Jie ^a,b   Gao, Ming ^b   Gao, Fen Fei ^b,c   Su, Quan Xi ^a   Wu, Jie ^a,b,c  

^a Yunfu People's Hospital   (China)

^b BARROW NEUROLOGICAL INSTITUTE   (United States)

^c SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

brain cannabinoid receptor 2; cannabis; drug addiction; GPCR; neurological disorders; neuronal excitability; psychiatric disorders

Indexed keywords

CANNABINOID 2 RECEPTOR; DOPAMINE; AJULEMIC ACID; CANNABINOID RECEPTOR AGONIST; DRONABINOL;

BRAIN; CENTRAL NERVOUS SYSTEM; DOPAMINE RELEASE; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HUMAN; MENTAL DISEASE; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; MENTAL DISORDERS; METABOLISM; NERVOUS SYSTEM DISEASES; PATHOLOGY;

ANIMALS; BRAIN; CANNABINOID RECEPTOR AGONISTS; DRONABINOL; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; RECEPTOR, CANNABINOID, CB2;

EID: 85016105312     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2016.149     Document Type: Review

References (76)

1. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
2. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
3. 2: a characterization of expression and adenyl-ate cyclase modulation within the immune system. Toxicol Appl Pharmacol 1997; 142: 278-87.
4. 2 receptor participation. J Pharmacol Exp Ther 1999; 289: 1620-5.
5. 1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24: 2708-15.
6. 2 receptor. Eur J Pharmacol 2000; 396: 141-9.
7. Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008; 153: 309-18.
8. Miller LK, Devi LA. The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev 2011; 63: 461-70.
9. 2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 2008; 1139: 434-49.
10. 2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psycho-pharmacol (Oxford) 2012; 26: 92-103.
11. 2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci USA 2014; 111: E5007-15.
12. Pacher P, Mechoulam R. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 50: 193-211.
13. 2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 2008; 286: S91-6.
14. Cécyre B, Thomas S, Ptito M, Casanova C, Bouchard JF. Evaluation of the specifcity of antibodies raised against cannabinoid receptor type 2 in the mouse retina. Naunyn Schmiedebergs Arch Pharmacol 2014; 387: 175-84.
15. 2 form functional heteromers in brain. J Biol Chem 2012; 287: 20851-65.
16. 2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission. J Physiol (Lond) 2015; 593: 871-86.
17. Stempel AV, Stumpf A, Zhang HY, Özdogan T, Pannasch U, Theis AK, et al. Cannabinoid type 2 receptors mediate a cell type-specifc plasticity in the hippocampus. Neuron 2016; 90: 795-809.
18. 2 receptor-dependent inhibition of dopamine release. Neuron 2016; 91: 1244-52.
19. Lanciego JL, Barroso-Chinea P, Rico AJ, Conte-Perales L, Callén L, Roda E, et al. Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. J Psycho-pharma col (Oxford) 2011; 25: 97-104.
20. 2 cannabinoid receptor mRNA in adult rat retina. Vis Neurosci 2000; 17: 91-5.
21. 2 isoforms, differential tissue expres sion and regulation by cannabinoid receptor ligands. Genes Brain Behav 2009; 8: 519-30.
22. A receptors. Br J Pharmacol 2012; 165: 951-64.
23. 2 receptor-mediated regulation of impulsive-like behaviour in DBA/2 mice. Br J Pharmacol 2012; 165: 260-73.
24. 2 cannabinoid receptor mRNAs in the mouse hippocampus. Neuroscience 2015; 311: 253-67.
25. 2 receptors. Science 2005; 310: 329-32.
26. 2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 2009; 29: 4564-70.
27. 2 receptor in the rat cerebellum: an immuno histo-chemical study. Neurosci Lett 2006; 396: 113-6.
28. 2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol 2008; 128: 961-7.
29. 2 cannabinoid receptors in the rat hippocampus. Synapse 2008; 62: 944-9.
30. 2 receptors: Immunohistochemical localization in rat brain. Brain Research 2006; 1071: 10-23.
31. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 2010; 58: 1017-30.
32. Cabral GA, Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J Leukoc Biol 2005; 78: 1192-7.
33. 2 receptors in the brain: role in central immune function. Br J Pharmacol 2008; 153: 240-51.
34. Pazos MR, Núñez E, Benito C, Tolón RM, Romero J. Role of the endo-cannabinoid system in Alzheimer's disease: new perspectives. Life Sci 2004; 75: 1907-15.
35. Rivers JR, Ashton JC. The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. Cent Nerv Syst Agents Med Chem 2010; 10: 47-64.
36. Little JP, Villanueva EB, Klegeris A. Therapeutic potential of can-na binoids in the treatment of neuroinflammation associated with Parkinsons disease. Mini Rev Med Chem 2011; 11: 582-90.
37. Szabo B, Siemes S, Wallmichrath I. Inhibition of GABAergic neuro-transmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 2002; 15: 2057-61.
38. Dubreucq S, Durand A, Matias I, Bénard G, Richard E, Soria-Gomez E, et al. Ventral tegmental area cannabinoid type-1 receptors control voluntary exercise performance. Biol Psychiatry 2013; 73: 895-903.
39. 1 receptor expression by hippocampal GABAergic interneurons. Pfugers Arch 2016; 468: 727-37.
40. den Boon FS, Chameau P, Schaafsma-Zhao Q, van Aken W, Bari M, Oddi S, et al. Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci USA 2012; 109: 3534-9.
41. Vlachou S, Panagis G. Regulation of brain reward by the endo can-nabinoid system: a critical review of behavioral studies in animals. Curr Pharm Des 2014; 20: 2072-88.
42. 2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabeto-logia 2010; 53: 2629-40.
43. 2 receptors. Neurosci Lett 2011; 490: 82-4.
44. 2 cannabinoid receptors on food intake in neonatal chicks. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 2011; 197: 1143-7.
45. Flake NM, Zweifel LS. Behavioral effects of pulp exposure in mice lacking cannabinoid receptor 2. J Endod 2012; 38: 86-90.
46. 2 receptors. Br J Pharmacol 2010; 160: 1773-84.
47. 2 can-nabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice. J Psychopharmacol (Oxford) 2011; 25: 111-20.
48. 2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology 2011; 36: 1489-504.
49. 2 receptors modulate cocaine's actions in mice. Nat Neurosci 2011 14: 1160-6.
50. 2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine. Neuro-psychopharmacology 2013; 38: 2515-24.
51. 2 receptor in the reinforcing actions of ethanol. Addict Biol 2015; 20: 43-55.
52. Svízenská IH, Brázda V, Klusáková I, Dubový P. Bilateral changes of cannabinoid receptor type 2 protein and mRNA in the dorsal root ganglia of a rat neuropathic pain model. J Histochem Cytochem 2013; 61: 529-47.
53. 2 receptor agonist in stroke. PLoS One 2015; 10: e0132487.
54. Lopez-Rodriguez AB, Acaz-Fonseca E, Viveros MP, Garcia-Segura LM. Changes in cannabinoid receptors, aquaporin 4 and vimentin expres-sion after traumatic brain injury in adolescent male mice. Association with edema and neurological defcit. PLoS One 2015; 10: e0128782.
55. 2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease. Exp Neurol 2016; 283: 204-12.
56. 2 cannabinoid receptor as potential target against Alzheimer's disease. Front Neurosci 2016; 10: 243.
57. 2 receptor in neurotoxic and infammation-driven rat models of Parkinson's disease. Exp Neurol 2015; 269: 133-41.
58. Agudelo M, Yndart A, Morrison M, Figueroa G, Muñoz K, Samikkannu T, et al. Differential expression and functional role of cannabinoid genes in alcohol users. Drug Alcohol Depend 2013; 133: 789-93.
59. Rivera P, Miguéns M, Coria SM, Rubio L, Higuera-Matas A, Bermúdez-Silva FJ, et al. Cocaine self-administration differentially modulates the expression of endogenous cannabinoid system-related proteins in the hippocampus of Lewis vs Fischer 344 rats. Int J Neuro psycho-pharmacol 2013; 16: 1277-93.
60. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012; 367: 3353-63.
61. 2) selective agonists. J Med Chem 2013; 56: 8224-56.
62. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611.
63. 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 2003; 3: 62-7.
64. 2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007; 36: 26-35.
65. Beltramo M. Cannabinoid type 2 receptor as a target for chronic-pain. Mini Rev Med Chem 2009; 9: 11-25.
66. Rom S, Persidsky Y. Cannabinoid receptor 2: potential role in immuno-modula tion and neuroinflammation. J Neuroimmune Pharmacol 2013; 8: 608-20.
67. 2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am J Pathol 2013; 182: 928-39.
68. Capettini LS, Savergnini SQ, da Silva RF, Stergiopulos N, Santos RA, Mach F, et al. Update on the role of cannabinoid receptors after ischemic stroke. Mediators Infamm 2012; 2012: 824093.
69. Aso E, Ferrer I. Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic. Front Pharmacol 2014; 5: 37.
70. Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, et al. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol 2011; 163: 1365-78.
71. Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, et al. WIN55, 212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1, 2, 3, 6-tetra-hydropyridine mouse model of Parkinson's disease. Eur J Neurosci 2009; 29: 2177-86.
72. García C, Palomo-Garo C, García-Arencibia M, Ramos J, Pertwee R, Fernández-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease. Br J Pharmacol 2011; 163: 1495-506.
73. 2 receptor as a pharmacological target against inflammation in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2016; 64: 200-8.
74. 2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009; 132: 3152-64.
75. 2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009; 57: 1154-67.
76. Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009; 156: 397-411.